OncoVent Biomedical Technology

Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has entered into a licensing agreement with Taiwan-based Orient EuroPharma Co., Ltd for the immunotherapy drug oregovomab. The agreement grants Orient exclusive commercialization rights to oregovomab in Taiwan, with additional preemptive rights for exclusive sales, marketing,…